Day One Biopharmaceuticals Inc
NASDAQ: DAWN · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-23
Day One Biopharmaceuticals Inc (DAWN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item |
|---|
| Total assets |
| Cash & equivalents |
| Current assets |
| Total liabilities |
| Current liabilities |
| Long-term debt |
| Shareholder equity |
| Retained earnings |
| Accounts receivable |
| Inventory |
| Goodwill |
Frequently asked questions
What is Day One Biopharmaceuticals Inc's revenue?
Day One Biopharmaceuticals Inc's trailing twelve-month revenue is $158.18M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is DAWN?
In its most recent fiscal year, DAWN ran a gross margin of 89.12%, an operating margin of -80.76%, and a net margin of -67.85%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does DAWN generate?
DAWN produced $-104.08M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.